Search academic texts

Information × Registration Number 0214U002629, 0111U000376 , R & D reports Title To explore possibility of radionuclide therapy and diagnostic in coplex treatment and monitoring of medullary cancer patients popup.stage_title Head Solodyannikova Oksana Ivanovna, Registration Date 22-01-2014 Organization Ukrainian Research Institute of Oncology and Radiology popup.description2 The object of study - 80 patients with medullary thyroid cancer. Aim of study: to improve the effectiveness of treatment and to estimate opportunities of radionuclide diagnostics methods as for to monitor medullary thyroid cancer patients (MTHC) and to develop radionuclide monitoring algorithm of these patients. Research methods and techniques - whole body scintigraphy with of 99mTc- karbomek , dynamic scintigraphy with 99mTc- karbomek , radionuclide therapy with 131I-MIBG, statistics , 2head gamma camera "Mediso" ( Hungary), single-photon emission computer tomography (SPECT) "E. CAM 180". Established that 131I-MIBG can be used in complex palliative treatment of metastatic medullary thyroid cancer, as well as preventive therapy in the postoperative phase. The effectiveness of 131I-MIBG therapy depends on the extent of tumor, functional foci activity, calcitonin levels and the number of treatment courses (reduction of absorbed dose with re-treatment). The five-year survival rate in the group of comparison (with 131I-MIBG and without) were not significantly different. At the same time, prolongation of disease in patients who received 131I-MIBG-therapy, were less - 36 % compared to 58 % in the other group accordingly (p. <0,05). Diagnostic informatively calculated for 99mTc (V)-DMSA (karbomek): sensitivity - 93.7 %, specificity - 77.2 % accuracy - 85.4 % ; for 131I-MIBG: sensitivity - 75.8 %, specificity - 90.6 % accuracy - 78.4%; for 99mTc - tektrotydu: sensitivity - 78.3%, specificity - 82.2% accuracy - 78.2%. Optimal radiopharmaceutical for scintigraphic monitoring of MTHC patients in the postoperative phase of disease is 99mTc (V)-DMSA because of high rates of sensitivity and accuracy and more profitability for follow up in clinical practice . The dynamic scintigraphy and indirect radionuclide angiography with 99mTc (V)-DMSA can improve the specificity of diagnostic studies and obtain additional differential diagnostic information. Whole body scintigraphy or SPECT with 99mTc (V)-DMSA in the postoperative monitoring of patients with MTHC should be performed in the time interval of 30-60 minutes after injection of radiopharmaceutical. A physical and technical support methods to obtain quantitative characteristics of dynamic scintigraphy with 99mTc-karbomek is developed. The radionuclide therapy algorithm and MTHC patients monitoring determines the place of radionuclide diagnostic and therapeutic methods and allows to improve management of these patients in the postoperative phase. Product Description popup.authors Даниленко Вікторія Вікторівна Джужа Дмитро Олександрович Міхайленко Валерій Євгенович Сукач Георгій Георгійович popup.nrat_date 2020-04-02 Close